Overview
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
Associated Conditions
- Cardiovascular Events
- Diabetic Nephropathy
- Heart Failure
- Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/02/07 | Phase 2 | Not yet recruiting | Tyler J Curiel | ||
2024/10/18 | Phase 3 | Recruiting | THPharm Corp. | ||
2024/07/03 | Phase 2 | Recruiting | |||
2024/05/28 | Phase 4 | Recruiting | |||
2023/12/13 | Early Phase 1 | Recruiting | Tyler J Curiel | ||
2023/05/06 | Phase 4 | Not yet recruiting | |||
2022/04/12 | Phase 2 | Completed | Dr. Frank Behrens | ||
2022/02/03 | Phase 1 | UNKNOWN | |||
2021/09/10 | Phase 1 | Completed | |||
2021/06/10 | Phase 2 | UNKNOWN |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Inc., USA | 68462-841 | ORAL | 80 mg in 1 1 | 8/3/2023 | |
| AvKARE | 42291-791 | ORAL | 40 mg in 1 1 | 1/10/2024 | |
| Physicians Total Care, Inc. | 54868-4605 | ORAL | 80 mg in 1 1 | 2/14/2012 | |
| Truemed Group LLC | 82922-037 | ORAL | 80 mg in 1 1 | 8/11/2022 | |
| Chartwell RX, LLC. | 62135-537 | ORAL | 80 mg in 1 1 | 3/10/2023 | |
| A-S Medication Solutions | 50090-5490 | ORAL | 40 mg in 1 1 | 3/22/2018 | |
| Lupin Pharmaceuticals, Inc. | 68180-199 | ORAL | 80 mg in 1 1 | 12/15/2023 | |
| Modavar Pharmaceuticals LLC | 72241-017 | ORAL | 80 mg in 1 1 | 8/23/2023 | |
| Aurobindo Pharma Limited | 65862-976 | ORAL | 40 mg in 1 1 | 1/13/2023 | |
| Physicians Total Care, Inc. | 54868-4539 | ORAL | 40 mg in 1 1 | 2/14/2012 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 6/4/2010 | ||
Authorised | 12/16/1998 | ||
Authorised | 10/3/2011 | ||
Authorised | 12/11/1998 | ||
Authorised | 12/16/1998 | ||
Authorised | 9/29/2010 | ||
Authorised | 3/13/2013 | ||
Authorised | 3/13/2013 | ||
Authorised | 3/13/2013 | ||
Authorised | 4/19/2002 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| Twynsta Tablet 80mg/5mg | SIN14010P | TABLET | 80.000 mg | 9/9/2011 | |
| TELSTAN 20 TABLET 20 mg | SIN14615P | TABLET | 20 mg | 9/12/2014 | |
| TOLURA TABLET 80MG | SIN15279P | TABLET | 80.00 mg | 7/3/2017 | |
| Twynsta Tablet 80mg/10mg | SIN14011P | TABLET | 80.000mg | 9/9/2011 | |
| TELSTAN 80 TABLET 80 mg | SIN14613P | TABLET | 80 mg | 9/12/2014 | |
| CO-MIDIS TABLETS 80MG/5MG | SIN16647P | TABLET | 80 mg | 11/24/2022 | |
| TELSTAN-H 80/12.5 TABLET 80 mg/12.5 mg | SIN14602P | TABLET | 80 mg | 9/3/2014 | |
| CORXEVA TABLET 40 MG | SIN16850P | TABLET | 40.0 MG | 8/31/2023 | |
| CORXEVA TABLET 80 MG | SIN16851P | TABLET | 80.0 MG | 8/31/2023 | |
| TELCORD 40 TABLET 40 MG | SIN16640P | TABLET | 40 MG | 11/11/2022 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Telmisartan Capsules | 国药准字H20133328 | 化学药品 | 胶囊剂 | 8/25/2023 | |
| Telmisartan Capsules | 国药准字H20080188 | 化学药品 | 胶囊剂 | 4/15/2022 | |
| Telmisartan Capsules | 国药准字H20051852 | 化学药品 | 胶囊剂 | 8/12/2020 | |
| Telmisartan Capsules | 国药准字H20051671 | 化学药品 | 胶囊剂 | 2/26/2021 | |
| Telmisartan Capsules | 国药准字H20041900 | 化学药品 | 胶囊剂 | 7/24/2020 | |
| Telmisartan Capsules | 国药准字H20090300 | 化学药品 | 胶囊剂 | 2/28/2024 | |
| Telmisartan Capsules | 国药准字H20080331 | 化学药品 | 胶囊剂 | 3/1/2023 | |
| Telmisartan Capsules | 国药准字H20052540 | 化学药品 | 胶囊剂 | 7/23/2020 | |
| Telmisartan Capsules | 国药准字H20070113 | 化学药品 | 胶囊剂 | 10/13/2023 | |
| Telmisartan Capsules | 国药准字H20100159 | 化学药品 | 胶囊剂 | 8/10/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| MICAVID TABLETS 80MG | N/A | N/A | N/A | 1/20/2021 | |
| TELMISARTAN TABLETS 80MG | N/A | N/A | N/A | 12/9/2020 | |
| TELMISARTAN TABLETS 40MG | N/A | N/A | N/A | 8/4/2017 | |
| TELMISARTAN TABLETS 40MG | N/A | N/A | N/A | 12/9/2020 | |
| TELMISARTAN PLUS HCT STADA TABLETS 80MG/12.5MG | N/A | N/A | N/A | 4/18/2018 | |
| TELMISARTAN PLUS HCT STADA TABLETS 40MG/12.5MG | N/A | N/A | N/A | 4/18/2018 | |
| TELMISARTAN TABLETS 80MG | N/A | N/A | N/A | 8/4/2017 |